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Parag H. Joshi, MD, MHS, Seth S. Martin, MD, MHS, Roger S. Blumenthal, MDD espite the success of statin therapy inreducing atherosclerotic cardiovasculardisease (ASCVD), there remains a large
residual risk for recurrent events in statin-treated
patients (1). Although residual risk may be attribut-
able to many factors (i.e., smoking, elevated glucose,
or blood pressure), there is considerable interest in
lipoprotein-related residual risk beyond low-density
lipoprotein (LDL)-cholesterol reduction obtained
with the use of statins. Triglycerides (TGs), a surro-
gate marker of TG-rich remnant lipoproteins (rem-
nants), have been a particular source of interest
because of a consistent association with ASCVD and
the increase in TG levels associated with the obesity
epidemic (2).SEE PAGE 2267In this issue of the Journal, Schwartz et al. (3)
leveraged 2 complementary trials to examine
the association of fasting TG levels with recurrent
ASCVD in statin-treated participants. The inves-
tigators performed post-hoc analyses of 1,501 partic-
ipants from the short-term MIRACL (Myocardial
Ischemia Reduction with Aggressive Cholesterol
Lowering) trial, performed in the late 1990s, and
15,871 participants from the recent longer-term
dal-OUTCOMES (A Study of RO4607381 in Stable
Coronary Heart Disease Patients With Recent Acute
Coronary Syndrome) trial (4,5). These trials provide*Editorials published in the Journal of the American College of Cardiology
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conducted and demonstrate the evolution of sec-
ondary prevention strategies. The authors found a
consistent, signiﬁcant, 50% to 60% increase in hazard
for recurrent events among those in the highest TG
categories compared with those in the lowest, after
adjustment for several risk factors and independent
of LDL-cholesterol levels (3).
The differences between the trials merit atten-
tion. The event rate among statin-treated patients
(i.e., residual risk) was strikingly high at 15%
over only 16 weeks in MIRACL. This was mark-
edly improved a decade later, though still high at
nearly 8% over 31 months in dal-OUTCOMES. Both
trials enrolled patients shortly after ACS, although
MIRACL participants did not undergo revasculariza-
tion, which had become standard of care by the time
dal-OUTCOMES was conducted. The difference in
treatment strategies probably contributed to the
discrepancy in event rates while also providing
a spectrum of risk ranging from the lower-risk
dal-OUTCOMES population to the higher-risk, statin-
naive MIRACL population. The consistent association
of TG with risk across these diverse populations is
timely, given recent ﬁndings related to ASCVD and
remnants.
Just as LDL-cholesterol serves as a surrogate mea-
sure of LDL particles, TGs serve as a surrogate mea-
sure of remnant lipoproteins. Whereas LDL particles
directly contribute to atherosclerosis, there has been
uncertainty over the direct contribution of remnants
to atherosclerosis because of their larger size. How-
ever, a series of Mendelian randomization studies
have elegantly supported a causal role for remnants
in atherosclerosis (6–9).
In a large Danish population, investigators found
that genetic elevations in nonfasting TGs led to a
nearly 90% increased odds of myocardial infarction
(6). Similarly, Varbo et al. (7) showed a 2.8-fold higher
causal odds of ischemic heart disease for each
39-mg/dl increase in remnant cholesterol (estimated
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2277as TG/5). Finally, 2 studies showed that a loss of
function of apoC3, a key inhibitor of remnant metab-
olism, led to a lifetime of low remnant levels (as
marked by TGs) and markedly reduced ASCVD (8,9).
The ﬁndings of Schwartz et al. (3) are consistent
with a post-hoc analysis of short-term follow-up
in the PROVE IT-TIMI 22 Trial, which also showed
a reduction in recurrent events with lower on-
treatment TG levels in statin-treated participants,
independent of LDL-cholesterol (10). The present
study extends these ﬁndings to more participants
over longer follow-up periods. Future work can
examine the risk associated with more direct
measures of remnants, such as remnant lipoprotein
cholesterol levels obtained by ultracentrifugation,
rather than surrogates, such as TGs.
The questions of whether residual risk for recur-
rent ASCVD can be attributed to remnant lipopro-
teins, and to what degree, carry signiﬁcant potential
therapeutic implications. With the rise in metabolic
syndrome and resultant increases in remnants, life-
style modiﬁcations take on even greater importance
as part of a structured preventive program. Inspired
by the simple elegance of the iconic Jackson 5, we
prefer the ABCs approach to prevention (11). Specif-
ically, modest weight loss may reduce TG by w20%
and moderate to intense physical activity may reduce
TGs by w20% to 30% (2).
Although clinicians are armed with many non-
statin lipid-lowering therapies, trials assessing their
efﬁcacy to reduce residual risk beyond statin therapyhave mostly disappointed (5,12,13), with the recent
exception of ezetimibe. However, there was a strong
suggestion of beneﬁt from niacin and ﬁbrates in the
subgroup with elevated TG and low HDL-cholesterol
(12,14). Eicosapentaenoic acid (EPA) (“ﬁsh oil”), a
strong TG reducer, has also had an inconsistent
effect on ASCVD (15,16). Two large event-driven tri-
als testing the addition of EPA to statins should
provide deﬁnitive evidence for this class (17,18).
Furthermore, development of pharmacotherapies
targeting remnants by inhibition of apoC3 is well
underway (19).
Schwartz et al. (3) add strong support that a
residually high TG level on statin therapy is a
biomarker of risk. Only more compelling random-
ized, controlled trial results showing a reduction in
ASCVD among participants on statins and under-
going intensive lifestyle therapy, but with residual
remnant elevation, will tell us if TG or remnants
in particular must be a target of pharmacotherapy.
For now, clinicians and patients must follow the
familiar exhortation of football coach Bill Beli-
chick: “Do your job!” refers to comprehensive
risk factor modiﬁcation with the use of proven
pharmacologic therapy and lifestyle modiﬁcation to
lower future ASCVD risk.
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